全球获取 CAR-T 细胞的挑战:亚洲视角。

Blood cell therapy Pub Date : 2023-12-28 eCollection Date: 2024-02-25 DOI:10.31547/bct-2023-023
William Yk Hwang, Satoshi Takahashi, Bryan Choi, He Huang, Shin Kawamata, Soo Chin Ng, Pawan Gupta, Amir Ali Hamidieh, Chaiyong Koaykul, Cospiahadi Irawan, Alok Srivastava
{"title":"全球获取 CAR-T 细胞的挑战:亚洲视角。","authors":"William Yk Hwang, Satoshi Takahashi, Bryan Choi, He Huang, Shin Kawamata, Soo Chin Ng, Pawan Gupta, Amir Ali Hamidieh, Chaiyong Koaykul, Cospiahadi Irawan, Alok Srivastava","doi":"10.31547/bct-2023-023","DOIUrl":null,"url":null,"abstract":"<p><p>The use of cell therapy for clinical applications has seen a dramatic increase in recent years, primarily in oncology, especially with the use of chimeric antigen receptor (CAR) T-cell therapies. However, there are some barriers to the widespread adoption of CAR-T cell therapies globally, primarily because of the high cost of manufacturing these cells and clinical infrastructure considerations. We reviewed the different strategies adopted across Asia to implement CAR-T cell therapy and found that these included patient assistance programs, close engagement with funders, cost-effectiveness studies, on-site manufacturing of CAR-T cells, and joint ventures between local partners and foreign pharmaceutical companies. Although on-site manufacturing can reduce the cost of genetic engineering and expansion, it does not address many other hidden costs and quality considerations. Future growth in large-scale regional manufacturing, facilitated by cutting-edge science and innovation, could reduce costs through economies of scale and facilitate the eagerly needed global access.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"7 1","pages":"10-13"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10937087/pdf/","citationCount":"0","resultStr":"{\"title\":\"Challenges in Global Access to CAR-T cells: an Asian Perspective.\",\"authors\":\"William Yk Hwang, Satoshi Takahashi, Bryan Choi, He Huang, Shin Kawamata, Soo Chin Ng, Pawan Gupta, Amir Ali Hamidieh, Chaiyong Koaykul, Cospiahadi Irawan, Alok Srivastava\",\"doi\":\"10.31547/bct-2023-023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The use of cell therapy for clinical applications has seen a dramatic increase in recent years, primarily in oncology, especially with the use of chimeric antigen receptor (CAR) T-cell therapies. However, there are some barriers to the widespread adoption of CAR-T cell therapies globally, primarily because of the high cost of manufacturing these cells and clinical infrastructure considerations. We reviewed the different strategies adopted across Asia to implement CAR-T cell therapy and found that these included patient assistance programs, close engagement with funders, cost-effectiveness studies, on-site manufacturing of CAR-T cells, and joint ventures between local partners and foreign pharmaceutical companies. Although on-site manufacturing can reduce the cost of genetic engineering and expansion, it does not address many other hidden costs and quality considerations. Future growth in large-scale regional manufacturing, facilitated by cutting-edge science and innovation, could reduce costs through economies of scale and facilitate the eagerly needed global access.</p>\",\"PeriodicalId\":72423,\"journal\":{\"name\":\"Blood cell therapy\",\"volume\":\"7 1\",\"pages\":\"10-13\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10937087/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood cell therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31547/bct-2023-023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/2/25 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood cell therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31547/bct-2023-023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/25 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

近年来,细胞疗法的临床应用急剧增加,主要是在肿瘤学领域,尤其是嵌合抗原受体(CAR)T 细胞疗法的应用。然而,CAR-T 细胞疗法在全球范围内的广泛应用还面临一些障碍,主要是因为制造这些细胞的成本较高,而且临床基础设施也需要考虑。我们回顾了亚洲各国为实施CAR-T细胞疗法而采取的不同策略,发现这些策略包括患者援助计划、与资助方密切接触、成本效益研究、现场制造CAR-T细胞,以及当地合作伙伴与外国制药公司之间的合资企业。虽然现场制造可以降低基因工程和扩增的成本,但并不能解决许多其他隐性成本和质量问题。未来,在前沿科学和创新的推动下,大规模区域制造的发展可以通过规模经济降低成本,并促进急需的全球准入。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Challenges in Global Access to CAR-T cells: an Asian Perspective.

The use of cell therapy for clinical applications has seen a dramatic increase in recent years, primarily in oncology, especially with the use of chimeric antigen receptor (CAR) T-cell therapies. However, there are some barriers to the widespread adoption of CAR-T cell therapies globally, primarily because of the high cost of manufacturing these cells and clinical infrastructure considerations. We reviewed the different strategies adopted across Asia to implement CAR-T cell therapy and found that these included patient assistance programs, close engagement with funders, cost-effectiveness studies, on-site manufacturing of CAR-T cells, and joint ventures between local partners and foreign pharmaceutical companies. Although on-site manufacturing can reduce the cost of genetic engineering and expansion, it does not address many other hidden costs and quality considerations. Future growth in large-scale regional manufacturing, facilitated by cutting-edge science and innovation, could reduce costs through economies of scale and facilitate the eagerly needed global access.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信